Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma - Wikidata - awgldk - TriplyDB

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

http://www.wikidata.org/entity/Q24643447

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs Next-generation prognostic assessment for diffuse large B-cell lymphoma New molecular targets in mantle cell lymphoma How I treat HIV-associated lymphoma Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update Next-generation surveillance strategies for patients with lymphoma Diffuse large B-cell lymphoma: current strategies and future directions Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma Inflammation meets cancer, with NF-κB as the matchmaker Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.Oncogenic activation of NF-kappaB.Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays.Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.My treatment approach to patients with diffuse large B-cell lymphoma.Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies Targeted therapy in lymphoma.Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response.Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.

P2860

Q24597424-7D50A56F-592B-4D5F-84FD-0A8FAF3C4C2E Q24618086-F2DF886E-FEFA-4E6D-9941-2DFF543218B7 Q26796428-CEE00BC2-B0BF-4ADA-88B9-9520225B6526 Q26821766-9E686CBE-A072-4C38-A6E7-F6F35F12B2CC Q26821860-6E9EAD8C-FDE9-4B89-B19F-CBF18FB53EA5 Q27304386-1EA14F07-753E-48E8-A3CF-B4C789017E9C Q28067817-962B3F36-FA51-452A-9B52-1809E71B1DC2 Q28078869-6B1F9333-2F8C-4281-AAB6-871B2C28EBCB Q28084956-E324AF88-9A17-43B9-85F6-24F65E98EFBE Q28269136-4E4FDCA1-BF2C-4238-96CE-28E0EAB8A033 Q28481321-1FBC8251-A158-4B54-A48F-5AF7E520F125 Q28649793-4CCD69E0-E073-4F8F-8AA6-F96EF4CE3C19 Q29620242-F8C359F1-4C23-4820-9C3F-B35D50FFAE08 Q30455450-15C43E6F-B7E7-498A-92DB-B78A10C0B514 Q30967984-322A2AB1-37BD-4E75-88E3-FD6FB4D27568 Q33385670-A9D8FA29-B175-4491-889E-AD8AE8C6DB71 Q33391725-12A50D25-9338-4A7E-B112-93D70E52F234 Q33404090-4F6A313E-4243-47CA-B072-0F4E47ADA0C2 Q33418257-F3C862FC-2977-4F07-8B6D-CFD5C9CC4230 Q33424956-7322F7A4-BCC3-4541-B169-78BEBCAAE14A Q33591789-E91B87F3-0395-42B1-A6B4-98D9D1793E57 Q33805988-B92CE86A-8F44-4403-A63B-027F79A2A890 Q33846801-6C89EA4F-BD4A-42FD-9304-CDCE9D15983E Q33849388-1644BB79-86F7-405F-97D2-A5C3BF370E59 Q33851726-1AEAB7CC-4EA6-4D28-A4FC-22BDF6D4D554 Q33889168-D940D27C-3F9A-4AB3-A0FB-A0E1E06AF353 Q33896749-C15137CD-E5C8-46AE-A320-55BB64CE0329 Q34032232-6ACA23C0-DF12-43A5-AB86-FA20010FBB2C Q34084858-3DEF388E-FE7E-48BE-BBBA-DAB8B2F0B067 Q34104112-4D988159-0A78-4CED-A505-6D27CB084AAF Q34251964-6D3D460D-42B5-4005-A6C8-034013638794 Q34372977-EC8E29E4-A255-4089-AA68-D53987765BF5 Q34390837-DD689889-FA9B-484F-9C06-2288BC8D1A90 Q34413686-62010704-927B-48CF-B4B1-2FCB6FD4CD88 Q34483455-D58AF0E7-16E3-484D-A162-AFD0A6203BA3 Q34568868-329CCF92-0DC0-48BF-B170-0C166B211D62 Q34646755-F5C6A693-B04A-487E-82A7-E89257706FD5 Q34679166-4B30FD3C-255C-42F0-A59B-79B07B995893 Q34707136-047C727E-AA8C-454F-92B4-C98F3AE677AA Q34750551-9C6A79A5-0EB0-4297-8DE5-A6D8612273C7

P2860

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

http://www.wikidata.org/entity/Q24643447

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@ast

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@en

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@nl

type

label

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@ast

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@en

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@nl

prefLabel

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@ast

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@en

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@nl

P1433

Q24643447-F7879916-2218-4BCC-89D1-47B59C04AA22

P1476

Q24643447-141D26CE-9EB1-4AD3-960F-ABF9C91D938C

P2093

Q24643447-028259A0-6D66-4872-B64C-D5972F05742A

Q24643447-0EF52746-7F3A-4DD6-8905-887415B9F8E0

Q24643447-3EB40DE1-146B-4D2D-B41A-EED1D3DE293E

Q24643447-41AFEEAA-30C9-4E9E-B808-D9ADF76FCE5C

Q24643447-5A81E919-3530-40C7-9975-7136F8BAC39F

Q24643447-B631FF70-E2E2-4950-8781-CE8F6E0E8C3D

Q24643447-B8650503-66EC-4947-9FCC-360DF0A77CA9

Q24643447-E9BFA8F6-8B61-44F2-ABF2-40CD85F87BB5

Q24643447-EB2410EC-CD21-4BA0-BDBB-D476D0A4B25E

Q24643447-FC46D34E-0E8A-4845-BF9B-088D9ED014AB

P2860

Q24643447-0C2680DD-B302-47A5-B7D1-FE54E48A1E44

Q24643447-0E5F6100-E611-4BB8-B802-9EDB2CC0506A

Q24643447-11A0DD1D-2F0F-4607-B1F8-FF08F08D1CE1

Q24643447-1995E418-50F2-4686-ACAE-275A7EFBF060

Q24643447-20AAB038-AEA5-4D4F-84C9-97EC4F426E21

Q24643447-27F06A36-62A6-4999-AFD4-ADABFEED9803

Q24643447-3151922C-D220-4362-A4C1-079612629F7C

Q24643447-4D83C11A-DEDD-4B9C-B634-C62697A927C4

Q24643447-4EB3A65D-BE3D-44F3-ABE6-3891219B8142

Q24643447-53CFC154-989A-4BDA-8817-FCA85B32B0FA

P304

Q24643447-7C808157-F34A-40CE-A4A1-218D42F570F2

P31

Q24643447-AB4AC85B-DB86-4DEE-B01A-74C28DD05798

P3181

Q24643447-78033813-8568-4935-ACB0-018D75665F8D

P356

Q24643447-9EFAC432-E5BA-46D8-81E1-99F2A54D7B5B

P407

Q24643447-2F526E57-4030-43F7-B3E5-B324137B5F82

P433

Q24643447-840497CD-EA72-4199-B89D-359269E903FE

P478

Q24643447-55AF6AA3-59DF-49BF-9C73-74645BC1C747

P50

Q24643447-C3FCE4D1-E3D4-40AF-896E-FB314421FD69

P577

Q24643447-96832453-2A7F-4CCF-82CD-23FBC5220638

P5875

Q24643447-4DF73DD1-0015-4A11-9E1D-151985F520AA

P698

Q24643447-E0B4D230-A586-41A2-8B9C-5D287408C68C

P921

Q24643447-2016ADEB-D98F-4920-9FBA-A0B047F3EC6A

Q24643447-34521E51-D05D-4EAB-B0B8-0B6CA9B7B0E2

P932

Q24643447-9A380BAC-44F6-492F-A7F2-002C144CCF45

P3181

P356

BLOOD-2009-01-199679

P1433

P1476

Differential efficacy of borte ...... diffuse large B-cell lymphoma

@en

P2093

Elaine S Jaffe

http://www.w3.org/2001/XMLSchema#string

George Wright

http://www.w3.org/2001/XMLSchema#string

John E Janik

http://www.w3.org/2001/XMLSchema#string

Kieron Dunleavy

http://www.w3.org/2001/XMLSchema#string

Margaret Shovlin

http://www.w3.org/2001/XMLSchema#string

Myron S Czuczman

http://www.w3.org/2001/XMLSchema#string

Nicole Grant

http://www.w3.org/2001/XMLSchema#string

Sandeep S Dave

http://www.w3.org/2001/XMLSchema#string

Stefania Pittaluga

http://www.w3.org/2001/XMLSchema#string

Wyndham H Wilson

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Stromal gene signatures in large-B-cell lymphomas

Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.

A loss-of-function RNA interference screen for molecular targets in cancer.

P304

6069-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3158221

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2009-01-199679

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24311718

http://www.w3.org/2001/XMLSchema#string

P698

19380866

http://www.w3.org/2001/XMLSchema#string

P921

P932

2699229

http://www.w3.org/2001/XMLSchema#string